ConcertAI and Foundation Medicine struck a data collaboration to merge Foundation Medicine’s de‑identified genomic and multimodal data with ConcertAI’s clinically linked datasets, creating a combined resource covering nearly half a million patients. The partners said the integrated dataset includes genomic alteration calls, gene expression, IHC, whole‑slide images and clinical outcomes to support drug development and real‑world evidence studies. Separately, Israeli diagnostics company MeMed received a $2 million grant from the Israel Innovation Authority to create an acute‑care proteomics biobank to accelerate AI‑driven IVD development. MeMed said the biobank will link high‑resolution host‑response proteomics with acute‑care clinical data to validate AIVD tests for time‑critical decision support. Both moves reflect industry focus on richer clinical‑genomic‑proteomic datasets as foundations for diagnostics and AI product development.